A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient

A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient

After failure of anthracycline- and platinum-based therapy, no effective therapies exist for management of metastatic triple-negative breast cancer (TNBC). We report a case of metastatic TNBC harboring MCL1 amplification, as identified by comprehensive genomic profiling in the course of clinical car...

Full description

Bibliographic Details
Main Authors: Siraj M. Ali, Jessica Watson, Kai Wang, Jon H. Chung, Caitlin McMahon, Jeffrey S. Ross, Karel A. Dicke
Format: Article
Language:English
Published: Karger Publishers 2016-02-01
Series:Case Reports in Oncology
Subjects:
Everolimus
Triple-negative breast cancer
MCL1
BAP1
Sorafenib
Online Access:http://www.karger.com/Article/FullText/443371

Internet

http://www.karger.com/Article/FullText/443371

Similar Items